Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Agios Pharma ( (AGIO) ) is now available.
Agios Pharmaceuticals addressed a recent securities analyst report detailing adverse event data from the FDA’s reporting system concerning its drug PYRUKYND. The report highlighted four patient cases, but Agios maintains that the information has not changed the drug’s established benefit-risk profile. The company continues to prioritize patient safety through rigorous pharmacovigilance processes. Additionally, on August 4, 2025, the Saudi Food and Drug Authority approved PYRUKYND for treating adult patients with specific types of thalassemia, potentially expanding its market reach.
The most recent analyst rating on (AGIO) stock is a Hold with a $56.00 price target. To see the full list of analyst forecasts on Agios Pharma stock, see the AGIO Stock Forecast page.
Spark’s Take on AGIO Stock
According to Spark, TipRanks’ AI Analyst, AGIO is a Neutral.
Agios Pharma’s strengths lie in its strategic partnerships and strong financial resources, as evidenced by recent earnings call highlights. However, operational profitability and cash generation issues limit its stock score. While technical indicators suggest potential undervaluation, the company must address profitability and regulatory challenges.
To see Spark’s full report on AGIO stock, click here.
More about Agios Pharma
Agios Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing treatments for rare diseases. The company’s primary product, PYRUKYND, is approved in the U.S. for treating hemolytic anemia in adults with pyruvate kinase deficiency.
Average Trading Volume: 653,068
Technical Sentiment Signal: Hold
Current Market Cap: $2.03B
For detailed information about AGIO stock, go to TipRanks’ Stock Analysis page.